Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential

Código QR

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential

Marie Bastin, Fabrizio Andreelli Diabetology-Metabolism Department, Sorbonne Université, ICAN, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, F-75013, FranceCorrespondence: Fabrizio AndreelliDiabetology-Metabolism Depart...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bastin M, Andreelli F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	incretins type 2 diabetes co-agonists GLP-1 GIP body weight Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/3883c1c376704bc391285ed87542c6f5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice
por: Nakamura T, et al.
Publicado: (2021)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
por: Sikirica MV, et al.
Publicado: (2017)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Toomas Jagomäe, et al.
Publicado: (2021)

Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study
por: Muo IM, et al.
Publicado: (2019)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Campbell RK, et al.
Publicado: (2010)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee&nbsp;W Chia, et al.
Publicado: (2009)

The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes
por: Elena Vital'evna Kirienkova, et al.
Publicado: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Role of incretin based therapies in the treatment of diabetic kidney disease
por: Paola Fioretto, et al.
Publicado: (2018)

Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes
por: Pan X, et al.
Publicado: (2019)

Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy
por: Ciacci C, et al.
Publicado: (2021)

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
por: Tucci S
Publicado: (2010)

Associations of TCF7L2 rs11196218 (A/G) and GLP-1R rs761386 (C/T) Gene Polymorphisms with Obesity in Chinese Population
por: Xu T, et al.
Publicado: (2021)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Characteristics of Gut Microbiota in Cerulein-Induced Chronic Pancreatitis
por: Wu C, et al.
Publicado: (2021)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Masao Koike, et al.
Publicado: (2021)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin AA, et al.
Publicado: (2016)

Activation of the GLP-1 receptor by chloropyrimidine derivatives
por: Shaikha S. AlNeyadi, et al.
Publicado: (2021)

Significant increment in the prevalence of overweight and obesity documented between 1994 and 2008 in Mexican college students
por: Cuevas-Ramos D
Publicado: (2010)

Clinical effectiveness of quercetin supplementation in the management of weight loss: a pooled analysis of randomized controlled trials
por: Huang H, et al.
Publicado: (2019)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
por: Wharton S, et al.
Publicado: (2017)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via MA
Publicado: (2010)